€ 22.3
Key Takeaways
Risk factor
Poor trading liquidity
Profitability factor
Undervalued vs peers
About
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and...
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA, reasonably priced on P/FCF
Target Price
The average target price of PHIL.MI is 29 and suggests 29% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
